ADIA Nutrition Proudly Launches Adia Labs LLC and Begins Sales of Branded Stem Cell Products
ADIA Nutrition (OTC Pink: ADIA) has launched Adia Labs , a new division focused on regenerative medicine. The company introduces two key products: AdiaVita, a private-label umbilical cord stem cell product guaranteeing 100 million viable cells and 3 trillion exosomes per unit, and AdiaLink, an upcoming product offering 3.5 trillion exosomes per unit.
The launch was enabled through a partnership with an FDA-approved laboratory, allowing ADIA to offer these products under its own brand. The products are specifically designed for clinical research, studies, and trials, targeting a potential client base of over one million doctors and clinics nationwide.
These products aim to address various conditions, including autoimmune diseases, degenerative disorders, and injury recovery, focusing on non-invasive biological treatments. Doctors and clinics can purchase these products through adialabs.com.
ADIA Nutrition (OTC Pink: ADIA) ha lanciato Adia Labs, una nuova divisione focalizzata sulla medicina rigenerativa. L'azienda presenta due prodotti chiave: AdiaVita, un prodotto di cellule staminali da cordone ombelicale a marchio privato che garantisce 100 milioni di cellule vitali e 3 trilioni di esosomi per unità, e AdiaLink, un prodotto in arrivo che offrirà 3,5 trilioni di esosomi per unità.
Il lancio è stato possibile grazie a una partnership con un laboratorio approvato dalla FDA, che consente ad ADIA di offrire questi prodotti con il proprio marchio. I prodotti sono specificamente progettati per la ricerca clinica, studi e sperimentazioni, mirando a una potenziale clientela di oltre un milione di medici e cliniche a livello nazionale.
Questi prodotti mirano a trattare varie condizioni, tra cui malattie autoimmuni, disturbi degenerativi e recupero da infortuni, concentrandosi su trattamenti biologici non invasivi. I medici e le cliniche possono acquistare questi prodotti tramite adialabs.com.
ADIA Nutrition (OTC Pink: ADIA) ha lanzado Adia Labs, una nueva división centrada en la medicina regenerativa. La empresa presenta dos productos clave: AdiaVita, un producto de células madre de cordón umbilical de marca privada que garantiza 100 millones de células viables y 3 billones de exosomas por unidad, y AdiaLink, un producto próximo que ofrecerá 3,5 billones de exosomas por unidad.
El lanzamiento fue posible gracias a una asociación con un laboratorio aprobado por la FDA, lo que permite a ADIA ofrecer estos productos bajo su propia marca. Los productos están diseñados específicamente para investigación clínica, estudios y ensayos, dirigidos a una base de clientes potencial de más de un millón de médicos y clínicas en todo el país.
Estos productos tienen como objetivo abordar diversas condiciones, incluidas enfermedades autoinmunes, trastornos degenerativos y recuperación de lesiones, centrándose en tratamientos biológicos no invasivos. Los médicos y clínicas pueden comprar estos productos a través de adialabs.com.
ADIA Nutrition (OTC Pink: ADIA)는 Adia Labs라는 새로운 부서를 출시했습니다. 이 부서는 재생 의학에 중점을 두고 있습니다. 회사는 두 가지 주요 제품을 소개합니다: AdiaVita, 1억 개의 생존 가능한 세포와 3조 개의 엑소좀을 보장하는 사설 브랜드 제대혈 줄기세포 제품, 그리고 AdiaLink, 개당 3.5조 개의 엑소좀을 제공하는 향후 출시될 제품입니다.
이번 출시는 FDA 승인 실험실과의 파트너십을 통해 가능해졌으며, ADIA는 자사 브랜드로 이러한 제품을 제공할 수 있습니다. 이 제품들은 임상 연구, 연구 및 시험을 위해 특별히 설계되었으며, 전국적으로 백만 명 이상의 의사와 클리닉을 목표로 하고 있습니다.
이 제품들은 자가면역 질환, 퇴행성 장애 및 부상 회복을 포함한 다양한 질환을 해결하는 것을 목표로 하며, 비침습적인 생물학적 치료에 중점을 두고 있습니다. 의사와 클리닉은 adialabs.com을 통해 이 제품들을 구매할 수 있습니다.
ADIA Nutrition (OTC Pink: ADIA) a lancé Adia Labs, une nouvelle division axée sur la médecine régénérative. L'entreprise introduit deux produits clés : AdiaVita, un produit de cellules souches de cordon ombilical sous marque propre garantissant 100 millions de cellules viables et 3 billions d'exosomes par unité, et AdiaLink, un produit à venir offrant 3,5 billions d'exosomes par unité.
Le lancement a été rendu possible grâce à un partenariat avec un laboratoire approuvé par la FDA, permettant à ADIA d'offrir ces produits sous sa propre marque. Les produits sont spécifiquement conçus pour la recherche clinique, les études et les essais, ciblant une clientèle potentielle de plus d'un million de médecins et de cliniques à l'échelle nationale.
Ces produits visent à traiter diverses conditions, y compris les maladies auto-immunes, les troubles dégénératifs et la récupération après blessure, en se concentrant sur des traitements biologiques non invasifs. Les médecins et les cliniques peuvent acheter ces produits via adialabs.com.
ADIA Nutrition (OTC Pink: ADIA) hat Adia Labs gegründet, eine neue Abteilung, die sich auf regenerative Medizin konzentriert. Das Unternehmen stellt zwei Schlüsselprodukte vor: AdiaVita, ein Produkt mit Stammzellen aus der Nabelschnur, das 100 Millionen lebensfähige Zellen und 3 Billionen Exosomen pro Einheit garantiert, und AdiaLink, ein bevorstehendes Produkt, das 3,5 Billionen Exosomen pro Einheit anbieten wird.
Der Launch wurde durch eine Partnerschaft mit einem von der FDA zugelassenen Labor ermöglicht, was es ADIA erlaubt, diese Produkte unter eigener Marke anzubieten. Die Produkte sind speziell für klinische Forschung, Studien und Versuche konzipiert und richten sich an eine potenzielle Kundschaft von über einer Million Ärzten und Kliniken im ganzen Land.
Diese Produkte zielen darauf ab, verschiedene Erkrankungen zu behandeln, einschließlich Autoimmunerkrankungen, degenerativen Störungen und Verletzungsrehabilitation, und konzentrieren sich auf nicht-invasive biologischen Behandlungen. Ärzte und Kliniken können diese Produkte über adialabs.com erwerben.
- Partnership with FDA-approved laboratory secured
- Large potential market of over 1 million doctors/clinics
- Launch of new revenue stream through stem cell products
- Product differentiation with guaranteed cell/exosome counts
- None.
Winter Park, Florida--(Newsfile Corp. - February 20, 2025) - ADIA Nutrition Inc. (OTC Pink: ADIA), a trailblazer in healthcare and supplementation, proudly announces the launch of Adia Labs LLC, a new division dedicated to advancing regenerative medicine. This initiative underscores ADIA Nutrition's commitment to providing high-quality products for the research and medical community.
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/240585_img_5218.jpg
Introducing Adia Labs LLC: Adia Labs focuses on delivering premium regenerative medicine solutions, specifically tailored for clinical research, studies, and trials. The division introduces:
- AdiaVita: A private-label product featuring umbilical cord stem cells. Each unit of AdiaVita guarantees a minimum of 100 million viable cells and 3 trillion exosomes, designed to support advanced medical research and therapeutic applications. This product has undergone rigorous third-party verification to ensure unparalleled quality, purity, and potency.
- AdiaLink: Coming soon, this product will offer exosomes with a guaranteed count of 3.5 trillion per unit. It's specifically crafted for exclusive use in clinical studies, trials, and research by doctors and clinics, aiming to push the boundaries of medical science.
The establishment of Adia Labs was made possible through a groundbreaking deal with an esteemed FDA-approved laboratory. This partnership allows ADIA Nutrition to offer AdiaVita under its own brand, ensuring that the products meet the highest standards of efficacy and safety. This collaboration leverages the lab's expertise in stem cell technology, reinforcing ADIA Nutrition's mission to provide cutting-edge, quality-driven health solutions.
Larry Powalisz, CEO of ADIA Nutrition, stated, "Our expansion into regenerative medicine is more than just growth; it's a step towards redefining healthcare. With Adia Med and now Adia Labs, we are dedicated to advancing medical science while maintaining the highest standards of quality and safety. Through our research, we estimate that we have over one million doctors and/or clinics as our potential client base."
Adia Labs is set to meet the growing demand for non-invasive, biological treatments for various conditions, including autoimmune diseases, degenerative disorders, and recovery from injuries. With its unique composition, Adia Labs aims to offer an accessible and effective solution for those seeking the benefits of stem cell therapy.
Doctors and clinics nationwide can now purchase these umbilical cord stem cell and exosome products for research, trials, and studies from Adia Labs. For pricing and further information, they should visit adialabs.com.
With stem cells, Adia Med opens new avenues for repairing and regenerating damaged tissues, providing hope for various health conditions such as autoimmune or cognitive diseases.
This launch not only expands ADIA Nutrition's product line but also positions them at the forefront of regenerative medicine, promoting a future where innovative treatments are more accessible and effective.
For media inquiries or further information, please contact Larry Powalisz at ceo@adiamed.com or 321-788-0850.
About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.
Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.biolete.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/240585
FAQ
What products has ADIA Nutrition launched through Adia Labs in February 2025?
How many potential clients does ADIA estimate for their new stem cell products?
What medical conditions will ADIA's new stem cell products target?
What are the key specifications of ADIA's AdiaVita stem cell product?
Where can medical professionals purchase ADIA's new stem cell products?
